A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase 3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Aug 2017
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Atherosclerosis
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 09 Aug 2017 Planned End Date changed from 25 Jan 2019 to 31 Jan 2019.
- 09 Aug 2017 Planned primary completion date changed from 25 Jan 2019 to 31 Jan 2019.
- 10 Jun 2017 Biomarkers information updated